The GOFURTGO Study: AGITG Phase II Study of fixed dose rate gemcitabine–oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer

BACKGROUND: Locally advanced inoperable pancreatic cancer (LAPC) has a poor prognosis. By increasing intensity of systemic therapy combined with an established safe chemoradiation technique, our intention was to enhance the outcomes of LAPC. In preparation for phase III evaluation, the feasibility a...

Descripción completa

Detalles Bibliográficos
Autores principales: Goldstein, D, Spry, N, Cummins, M M, Brown, C, van Hazel, G A, Carroll, S, Selva-Nayagam, S, Borg, M, Ackland, S P, Wratten, C, Shapiro, J, Porter, I W T, Hruby, G, Horvath, L, Bydder, S, Underhill, C, Harvey, J, Gebski, V J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3251866/
https://www.ncbi.nlm.nih.gov/pubmed/22134511
http://dx.doi.org/10.1038/bjc.2011.526

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3251866/
https://www.ncbi.nlm.nih.gov/pubmed/22134511
http://dx.doi.org/10.1038/bjc.2011.526

Ejemplares similares